Geoff Oxnard

Company: Loxo@Lilly

Job title: Vice President, Clinical Development, Global Head, Thoracic Cancer

Seminars:

Asking More of Small Molecule KRAS Inhibition: Combination with Immunotherapy & Beyond G12C 12:15 pm

• Overall prognosis remains poor for KRAS mutant patients • Olomorasib is a potent 2nd generation G12C inhibitor with early combination efficacy data suggesting olomorasib may be suited for 1L combinations with standard of care immunotherapy regimens in advanced NSCLC • Borrowing from the discovery learnings from olomorasib, a highly mutant-selective G12D inhibitor and an…Read more

day: Day Two Track B AM